VIR_logo_large.jpg
Vir Biotechnology to Host a Call on Sotrovimab’s Retained Activity Against the Omicron SARS-CoV-2 Variant
December 07, 2021 03:55 ET | Vir Biotechnology, Inc.
SAN FRANCISCO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) announced that Management will host a conference call at 8:30 am ET, Tuesday, December 7, 2021, to discuss new...
VIR_logo_large.jpg
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant
December 07, 2021 03:48 ET | Vir Biotechnology, Inc.
 – New preclinical findings generated through in vitro testing of sotrovimab againstthe complete pseudo-virus updated to bioRxiv – Data build on promising signal published last week, underscoring the...
22157.jpg
Global Research Antibodies Outlook to 2028: Rise in R&D Initiatives and an Increase in Neurobiology and Stem Cell Research are Key Factors in Market Advancement
December 03, 2021 11:23 ET | Research and Markets
Dublin, Dec. 03, 2021 (GLOBE NEWSWIRE) -- The "Global Research Antibodies Market Size, Share & Trends Analysis Report by Product (Primary, Secondary), by Type (Monoclonal Antibodies, Polyclonal...
VIR_logo_large.jpg
Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
December 02, 2021 02:07 ET | Vir Biotechnology, Inc.
 – Preclinical data demonstrate sotrovimab, authorized in multiple countries around the world, retains activity against all tested variants of concern, including key mutations of Omicron – – Data to...
22157.jpg
Unituxin Patent, Sales & Clinical Trials Guide 2021-2028, Featuring Bellicum Therapeutics, MabVax Therapeutics, Sinobioway Cell Therapy and United Therapeutic Corporation
November 26, 2021 06:58 ET | Research and Markets
Dublin, Nov. 26, 2021 (GLOBE NEWSWIRE) -- The "Unituxin Patent, Sales & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. Neuroblastoma is an embryonic...
vmr logo registered_ blue.png
Single-Use Bioreactors Market size worth $ 11,603.32 Million, Globally, by 2028 at 19.36% CAGR: Verified Market Research®
November 24, 2021 10:15 ET | Verified Market Research
Jersey City, New Jersey, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, “Single-Use Bioreactors Market” By Application (Process Development, Research, and...
22157.jpg
Emerging Issues in Biopharmaceutical Manufacturing in 2021
November 19, 2021 06:38 ET | Research and Markets
Dublin, Nov. 19, 2021 (GLOBE NEWSWIRE) -- The "18th Annual Report and Survey on Biopharmaceutical Manufacturing Capacity and Production" report has been added to ResearchAndMarkets.com's offering. ...
VIR_logo_large.jpg
GSK and Vir Biotechnology Announce United States Government Agreements to Purchase Sotrovimab, a COVID-19 Treatment
November 17, 2021 06:42 ET | Vir Biotechnology, Inc.
– US government contracts for approximately $1 billion1 (USD) now in place to purchase sotrovimab, further expanding access nationwide – – This brings the total number of doses secured through...
22157.jpg
Global $5.8 Billion Research Antibodies Market to 2028 with COVID-19 Being a Major Contributing Factor
November 15, 2021 04:38 ET | Research and Markets
Dublin, Nov. 15, 2021 (GLOBE NEWSWIRE) -- The "Research Antibodies Market Share, Size, Trends, Industry Analysis Report, By Product; By Type; By Technologies; By Source; By Application; By End-Use;...
VIR_logo_large.jpg
Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19
November 12, 2021 07:10 ET | Vir Biotechnology, Inc.
– COMET-TAIL Phase 3 data demonstrated that intramuscular administration of sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations – – The...